Danish BioInnovation Institute

Danish BioInnovation Institute (BII) is a venture capital firm focused on supporting early-stage start-ups and spin-out companies within human health, planetary health, and societal resilience. They aim to translate scientific breakthroughs into innovative products and solutions. BII provides funding, lab and office space, and comprehensive support to help entrepreneurs accelerate their journey towards validated ventures and company creation. Their programs include Venture Lab, Bio Studio, and Quantum Lab, each tailored to specific stages and areas of innovation. They actively foster a community where scientific discoveries can be transformed into viable businesses, contributing to a better world by addressing pressing global challenges in health and sustainability. They provide access to state-of-the-art laboratories, resources, and support systems to ensure their portfolio companies have the environment to thrive and develop cutting-edge technologies and solutions. BII operates through a series of focused programs designed to support start-ups at various stages. The Venture Lab program is for early-stage start-ups providing up to DKK 4M in funding to accelerate venture validation. The Bio Studio program supports entrepreneurial academic researchers in translating their science into innovative products and solutions, offering up to DKK 5.35M funding per year for three years. The Quantum Lab focuses on early-stage quantum technology startups in collaboration with NATO DIANA. In addition to funding, BII provides access to fully equipped laboratories, office spaces, and other essential infrastructure, allowing companies to focus on their research and development. BII's approach extends beyond mere financial investment. They provide extensive support services, including waste management, access to basic laboratory gases, consumables, and equipment, autoclaving and dishwashing services, and cryo/freezer storage space. They also assist with regulatory compliance, such as advising on work related to genetically modified organisms. This holistic support system is designed to minimize operational burdens and maximize the efficiency of their portfolio companies. By combining funding, facilities, and expertise, BII aims to create an ecosystem where innovation can flourish and impactful solutions can be developed and brought to market. BII demonstrates its commitment to creating societal impact through focusing its investments in areas critical to the future, such as human health, planetary health, and societal resilience. This is further supported by their collaborative environment in which portfolio companies can collaborate and leverage on shared knowledge and facilities. This is enhanced by the dedicated program support, specifically tailored to the needs of the different stages of growth and innovation. In addition, BII provides access to expert guidance, equipment, and facilities that enable the development and validation of novel technologies. By actively seeking and supporting changemakers, BII fosters an ecosystem conducive to the growth of innovative start-ups and spin-outs capable of addressing complex global challenges. They have achieved substantial traction, having supported 131 start-ups to date and contributing to the launch of 21 products on the market. With €139M in total funding and a portfolio that has collectively raised €1B in external funding, BII underscores its role as a significant catalyst for bioinnovation and a valuable partner for entrepreneurs seeking to translate scientific ideas into tangible solutions.

Human health, planetary health, societal resilience, Quantum technology

Core thematic spaces, technologies, and target market segments of interest.